Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.

The updated Covid-19 vaccine approvals follow the June FDA's Vaccines and Related Biological Products Advisory Committee ...

Gaithersburg, Maryland-based Novavax received ... it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine. Get breaking news and ...

Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for ... The deal with Sanofi breathes new life into ...

PR Newswire • 16 days ago Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized ... Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value ...

Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine ... licensing agreement which Novavax announced with healthcare giant Sanofi ...

RSV and Meningitis / travel vaccines will be the COVID vaccine developed by Novavax (NVAX) - as I wrote in a recent note on Novavax: By the terms of the deal, Sanofi made a $500m upfront payment ...

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...

Regulators approve its updated COVID-19 vaccine It may seem ... If not for a licensing agreement which Novavax announced with healthcare giant Sanofi earlier this year to develop products ...

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...